查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治療和診斷全球市場-2022-2029
市場調查報告書
商品編碼
1140694

非酒精性脂肪性肝炎治療和診斷全球市場-2022-2029

Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

非酒精性脂肪性肝炎生物標誌物研究將在預測期內繼續支持市場增長

增加研究活動以提高現有生物標誌物的生產力和效率或發現新的生物標誌物將為非酒精性脂肪性肝炎市場的增長創造重大機遇。預計。非酒精性脂肪性肝炎的患病率在全球範圍內急劇增加，從而增加了對各種診斷方法的需求。目前，非酒精性脂肪性肝炎的診斷方法包括活檢，這是一種侵入性手術。肝活檢仍然是診斷非酒精性脂肪性肝炎的最終標準，但它可能導致各種臨床並發症，包括創傷和出血。

政府通過計劃和舉措提供的支持也促進了全球市場的增長。越來越多的開發非酒精性脂肪性肝炎治療和診斷工具的計劃和舉措正在顯著推動市場的增長。例如，2021年，全球肝臟研究所公佈了美國NASH行動計劃。該計劃包括關於標準護理和協調護理途徑的更新指南、非侵入性診斷的採用和報銷、就以患者為中心的基於價值的護理和福利設計、公共衛生、監管和整合 NASH 對支付者和醫療保健系統進行調查。

地理滲透

北美將是預測期內的主要地區

北美在全球非酒精性脂肪性肝炎治療和診斷市場中佔據主導地位，預計在預測期內將保持其地位。在預測期內，美國將佔據北美非酒精性脂肪性肝炎治療和診斷市場的最大份額。市場增長的主要驅動力包括為生物標誌物研發提供大量資金的政府機構和製藥公司。此外，先進醫療設施的存在以及糖尿病、肥胖症和脂肪肝疾病患病率的上升也推動了該地區目標市場的增長。

據估計，在預測期內，亞太地區的非酒精性脂肪性肝炎治療和診斷市場將出現大幅增長。亞太地區的增長主要是由於醫療基礎設施的快速發展和對慢性肝病的認識不斷提高。此外，外資企業也正在向中國、印度等新興國家進軍。

競爭格局。

非酒精性脂肪性肝炎治療和診斷市場是一個競爭激烈的市場。為全球市場增長做出貢獻的領先非酒精性脂肪性肝炎治療和診斷製造商包括 Abbvie Inc.、Cadila Healthcare Limited、Genfit SA、Gilead Sciences Inc.、Novo Nordisk A/S、Quest Diagnostics，包括 Shire Plc、Siemens Healthineers 和賽默飛世爾科技公司主要參與者正在為非酒精性脂肪性肝炎治療和診斷市場的全球增長採用新產品發布和擴張戰略。 2020 年 2 月，Meridian Bioscience 簽訂了收購 exalenz bioscience 的最終協議。兩家公司的收購價約為4900萬美元。通過此次收購，Meridian 增加了 Exalenz 的旗艦 BreathID 呼吸測試系統，這是一種用於檢測幽門螺桿菌的尿素呼吸測試平台，通常與消化性潰瘍和胃潰瘍癌有關。 BreathID 進一步推進了 Meridian 成為胃腸道診斷解決方案領先供應商的戰略。該平台為成人和兒童患者提供對患者友好的非侵入性樣本採集和一流的靈敏度和特異性。同樣在 2021 年 12 月，賽默飛世爾科技宣布以 174 億美元收購 PPD，後者是一家為生物製藥和生物技術行業提供臨床研究服務的全球供應商。 PPD 服務於生物技術和生物製藥行業。

COVID-19 對全球非酒精性脂肪性肝炎治療和診斷市場的負面影響

COVID-19 大流行正在阻礙非酒精性脂肪性肝炎治療和診斷市場的增長。非酒精性脂肪性肝炎患者患 COVID-19 的風險明顯更高，但在危機期間新的診斷和治療方法正在下降。此外，將 COVID-19 疫苗轉用於研發減少了研究機構和其他私人組織正在進行的研究。因此，預計2020年非酒精性脂肪性肝炎治療和診斷的需求將降低市場價值增長。

全球非酒精性脂肪性肝炎治療和診斷市場報告提供了大約 76 個市場數據表、60 個圖表和 170 頁的結構。

內容

第 1 章調查方法及範圍

  • 調查方法
  • 市場範圍

第 2 章主要趨勢和發展

第 3 章執行摘要

  • 按診斷代理劃分的市場細分
  • 按藥物劃分的市場細分
  • 按銷售渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
    • 抑制因素
    • 商機
  • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措

第 7 章診斷

  • 診斷成像技術
  • 診斷測試
  • 活檢

第 8 章治療

  • Ocaliva
  • Elafibranor
  • Senikriviroku
  • Seronsertib
  • 其他

第 9 章按銷售渠道

  • 醫院藥房
  • 在線頻道
  • 零售渠道

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 競爭對手戰略分析
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Abbvie Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Cadila Healthcare Limited
  • Conatus Pharmaceuticals Inc.
  • Exalenz Bioscience Ltd.
  • Genfit SA
  • Gilead Sciences Inc.
  • Intercept Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Quest Diagnostics
  • Shire Plc
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

第 13 章 DataM

簡介目錄
Product Code: DMHCIT2968

Market Overview

Non-alcoholic steatohepatitis therapeutics and diagnostics market was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 22.31% during the forecast period (2022-2029).

Non-alcoholic steatohepatitis (NASH) is a common cause of chronic liver disease strongly associated with insulin resistance leading to fibrosis. Type 2 diabetes and NAFLD commonly exist together. NAFLD comprises simple steatosis (NAFL), non-alcoholic steatohepatitis, and cirrhosis. According to the National Institute of Health, in 2021, Type 2 diabetes results from the body's ineffective use of insulin. In year 2021 more than 95% of people with diabetes have type 2 diabetes. Hence the rising incidence and prevalence rate of diabetes creates significant scope for the non-alcoholic steatohepatitis therapeutics and diagnostics market. The rising prevalence of non-alcoholic steatohepatitis and the high prevalence of liver-related diseases are some factors that are expected to propel market growth.

Market Dynamics: Research for non-alcoholic steatohepatitis biomarkers will continue supporting the growth of the market during the forecast period

Increasing research activities to raise the already available biomarkers' productivity and efficiency or discover new ones is expected to create enormous opportunities for growth in the non-alcoholic steatohepatitis market. The prevalence of non-alcoholic steatohepatitis across the globe is increasing dramatically, driving the requirement for various diagnosis methods. The current method for the diagnosis of non-alcoholic steatohepatitis includes live biopsy, which is an invasive procedure. Although liver biopsy is still considered the most reliable standard for diagnosing non-alcoholic steatohepatitis, it can lead to various clinical complications such as trauma and bleeding.

Also, government support through programs and initiatives is driving the growth of the global market. Organizations' increasing number of programs and initiatives to develop non-alcoholic steatohepatitis drugs and diagnostic tools significantly drives the market's growth. For instance, in 2021, Global liver institute released U.S. NASH action plan. This plan included updated guidelines for standards of care and coordinated care pathways, adoption and reimbursement of non-invasive diagnostics, Payor and health system research on patient-centric value-based care and benefit design and Integration of NASH into public health, regulatory, and legislative priorities.

Market Segmentation: The diagnostic tests segment accounted for the highest share in global non-alcoholic steatohepatitis therapeutics and diagnostics market

Only a few diagnostic tests are available to diagnose non-alcoholic steatohepatitis, including liver function tests, lipid profile tests, and fibrosis assessment tests. The presence of non-alcoholic steatohepatitis is confirmed when the diagnostic results of the tissue show fat, inflammation, and damage to liver cells. Moreover, several in-vitro diagnostics tests set to be released in 2021 will support segmental growth worldwide. Therefore, diagnostic tests contribute a major share in the growth of the global non-alcoholic steatohepatitis therapeutics and diagnostics market.

Based on the therapeutics, the non-alcoholic steatohepatitis therapeutics and diagnostics market has been classified into Ocaliva, Elafibranor, Cenicriviroc, Selonsertib, and others. Moreover, the Selonsertib segment held a significant share of market growth. Selonsertib for patients with linking fibrosis or compensated cirrhosis due to non-alcoholic steatohepatitis. It is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), likely anti-inflammatory, antineoplastic, and anti-fibrotic activities. Selonsertib targets and ties to the catalytic kinase domain of ASK1 in an ATP-competitive approach; by this means, preventing its phosphorylation and activation. Therefore, Selonsertib contributes a considerable share to the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market across the globe.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global non-alcoholic steatohepatitis therapeutics and diagnostics market and is expected to retain its position during the forecast period. The US contributed the largest share in the North American non-alcoholic steatohepatitis therapeutics and diagnostics market in the forecast period. The primary factor contributing to the market's growth includes the significant funding provided by government organizations and pharmaceutical companies for the R&D of biomarkers. The presence of sophisticated healthcare amenities and the growing incidence of diabetes, obesity, and fatty liver disease support this region's target market's growth.

The Asia Pacific is estimated to grow at a considerable growth rate in the non-alcoholic steatohepatitis therapeutics and diagnostics market during the forecast period. The growth of Asia-Pacific is mainly attributed to the rapidly evolving healthcare infrastructure and increasing awareness of chronic liver conditions. Moreover, the expansion of foreign market players in the nation's emerging economies, such as China and India.

Competitive Landscape:

The non-alcoholic steatohepatitis therapeutics and diagnostics market is highly competitive. The key non-alcoholic steatohepatitis therapeutics and diagnostics players contributing to the global market's growth include Abbvie Inc., Cadila Healthcare Limited, Genfit SA, Gilead Sciences Inc., Novo Nordisk A/S, Quest Diagnostics, Shire Plc, Siemens Healthineers, Thermo Fisher Scientific Inc. The major players are adopting new product launches and expansion strategies for global growth in the non-alcoholic steatohepatitis therapeutics and diagnostics market. In February 2020, Meridian Bioscience signed a definitive agreement to acquired exalenz bioscience. The value of the acquisition of these two companies is around $49 million. By this acquisition, Meridian will be adding Exalenz's flagship BreathID Breath Test Systems, a urea breath test platform for detecting Helicobacter pylori, often associated with peptic ulcers and gastric ulcers cancer. BreathID furthers Meridian's strategy to be the leading provider of gastrointestinal diagnostic solutions. The platform offers patient-friendly, noninvasive sample collection and best-in-class sensitivity and specificity for adult and pediatric patients. Also, in December 2021, Thermo Fisher Scientific Inc. announced that it had completed its acquisition of PPD, Inc., a global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. PPD provided services to the biotech and biopharma industries.

COVID-19 Impact: Negative impact on the global non-alcoholic steatohepatitis therapeutics and diagnostics market

The COVID-19 pandemic has hampered the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market. Though the risk for the occurrence of COVID-19 is considerably high in patients suffering from non-alcoholic steatohepatitis, the new diagnosis and treatments have declined amidst the crisis. Moreover, the ongoing research in research institutes and other private organizations has been reduced due to a diversion in the R&D of the COVID-19 vaccine. Therefore, the demand for non-alcoholic steatohepatitis therapeutics and diagnostics is expected to decrease market value growth in 2020.

The global non-alcoholic steatohepatitis therapeutics and diagnostics market report would provide an access to approximately 76 market data tables, 60 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Diagnostics
  • 3.2. Market Snippet by Therapeutics
  • 3.3. Market Snippet by Sales Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Diagnostics

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnostics

Segment

    • 7.1.2. Market attractiveness index, By Diagnostics Segment
  • 7.2. Imaging Techniques *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Diagnostic Tests
  • 7.4. Biopsy

8. By Therapeutics

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Therapeutics Segment
    • 8.1.2. Market attractiveness index, By Therapeutics Segment
  • 8.2. Ocaliva *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Elafibranor
  • 8.4. Cenicriviroc
  • 8.5. Selonsertib
  • 8.6. Others

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Sales Channel Segment
    • 9.1.2. Market attractiveness index, By Sales Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Channel
  • 9.4. Retail Channel

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Abbvie Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cadila Healthcare Limited
  • 12.3. Conatus Pharmaceuticals Inc.
  • 12.4. Exalenz Bioscience Ltd.
  • 12.5. Genfit SA
  • 12.6. Gilead Sciences Inc.
  • 12.7. Intercept Pharmaceuticals Inc.
  • 12.8. Merck & Co., Inc.
  • 12.9. Novartis AG
  • 12.10. Novo Nordisk A/S
  • 12.11. Quest Diagnostics
  • 12.12. Shire Plc
  • 12.13. Siemens Healthineers
  • 12.14. Thermo Fisher Scientific Inc.
  • 12.15. WuXi AppTec
  • List not Exhaustive*

13. DataM

  • 13.1. Appendix
  • 13.2. About us and services
  • 13.3. Contact us